Acurx launches pilot trial of ibezapolstat in multiply recurrent C. difficile infection

• Acurx initiated start-up activities for a clinical trial of ibezapolstat in multiply recurrent C. difficile infection.
• First patient expected to enroll next quarter; program begins with a 20-patient open-label pilot in patients with at least 3 episodes in 12 months.
• Positive pilot results would inform an active-controlled Phase 3 registration trial in rCDI; approval path targeted under FDA’s Limited Population Pathway.
• Company also plans an international Phase 3 registration program in acute CDI, citing consistent feedback from the FDA and EMA.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acurx Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607140800PR_NEWS_USPR_____NY02838) on July 14, 2026, and is solely responsible for the information contained therein.